뒤로
Monopar Therapeutics Inc (MNPR) 수입
MNPR 주가 차트
MNPR 수입
Monopar Therapeutics Inc
$54.56
-4.19%
$-2.39
종가: Mar 26, 16:00:00 GMT-4
$54.56
0%
$0
애프터마켓: Mar 26, 18:53:08 GMT-4
최신 수익 결과: Q3 '25
보고됨: 2025-11-13
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
MNPR의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Monopar Therapeutics Inc MNPR의 지난 분기 매출 실적은 어땠나요?
Monopar Therapeutics Inc의 매출 추정치는 얼마인가요?
Monopar Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Monopar Therapeutics Inc는 언제 수익을 보고하나요?
Monopar Therapeutics Inc의 예상 수익은 얼마인가요?
Monopar Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$56.95
시가
$55.9
일일 범위
$54.28 - $58.12
52주 범위
$26.05 - $105
거래량
125.1K
평균 거래량
274.8K
배당수익률
--
EPS(TTM)
-3.44
시가총액
$364.4M
MNPR란 무엇인가요?
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.